Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
42 hedge funds and large institutions have $11.2M invested in Rubius Therapeutics, Inc in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 24 closing their positions.
32% less funds holding
Funds holding: 62 → 42 (-20)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
62% less capital invested
Capital invested by funds: $29.7M → $11.2M (-$18.5M)
79% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$168K |
| 2 |
Renaissance Technologies
New York
|
+$19.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16.6K |
| 4 |
E
Ergoteles
New York
|
+$15.8K |
| 5 |
VF
Virtu Financial
New York
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$295K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$236K |
| 3 |
AFM
Abbot Financial Management
Andover,
Massachusetts
|
-$196K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$184K |
| 5 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$152K |
RUBY Hedge Fund Activity: Q4 2022 in Review
42 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q4 2022, worth a combined $11.2M — down 62% from $29.7M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of RUBY and 5 opened new positions — a net loss of 19 holders — while 15 trimmed existing stakes and 10 added.
The largest buyer was Acadian Asset Management, adding an estimated $168K. The largest seller was Fidelity Investments, cutting an estimated $295K.
- 42 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q4 2022, down from 62 in Q3 2022.
- Funds reported $11.2M of Rubius Therapeutics, Inc stock for Q4 2022, down 62% quarter-over-quarter.
- 5 funds opened new Rubius Therapeutics, Inc positions in Q4 2022 and 24 closed out, a net change of -19 holders.
- The largest Rubius Therapeutics, Inc buyer in Q4 2022 was Acadian Asset Management, an estimated $168K added.
- The largest Rubius Therapeutics, Inc seller in Q4 2022 was Fidelity Investments, an estimated $295K sold.
Based on aggregated 13F filings for Q4 2022.